menu
    • menu
    [{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$40.0 million","newsHeadline":"LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Intravenous Infusion","sponsorNew":"Oneness Biotech \/ LEO Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ LEO Pharma"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Microbio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pan-COVID New Drug - SNS812 Achieves Superiority in Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2024","year":"2024","type":"Not Applicable","leadProduct":"SNS812","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Oneness Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oneness Biotech \/ Microbio","highestDevelopmentStatusID":null,"companyTruncated":"Oneness Biotech \/ Microbio"}]

    Find Clinical Drug Pipeline Developments & Deals by Oneness Biotech

    Menu

    Oneness Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oneness Biotech

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed

                            Oneness Biotech

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS812

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Microbio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pan-COVID New Drug - SNS812 Achieves Superiority in Phase 2 Study

                            Details : SNS812 achieves statistical significance with clinically meaningful endpoints in the Phase 2 trial and is the only therapeutic with a broad-spectrum efficacy in multiple coronavirus variants.

                            Brand Name : SNS812

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 10, 2024

                            Lead Product(s) : SNS812

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Microbio

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oneness Biotech

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed

                            Oneness Biotech

                            Taiwan arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB825

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Leo Pharma

                            Deal Size : $570.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825

                            Details : Oneness will be responsible for executing the Phase 2a study for Atopic Dermatitis in the United States and Microbio Shanghai will execute the Phase 2a study for allergic asthma in China.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $40.0 million

                            April 15, 2020

                            Lead Product(s) : FB825

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Leo Pharma

                            Deal Size : $570.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth